Design and Immunological Properties of the Novel Subunit Virus-like Vaccine against SARS-CoV-2
The COVID-19 pandemic is ongoing, and the need for safe and effective vaccines to prevent infection and to control spread of the virus remains urgent. Here, we report the development of a SARS-CoV-2 subunit vaccine candidate (Betuvax-CoV-2) based on RBD and SD1 domains of the spike (S) protein fused to a human IgG1 Fc fragment. The antigen is adsorbed on betulin adjuvant, forming spherical particles with a size of 100–180 nm, mimicking the size of viral particles. Here we confirm the potent immunostimulatory activity of betulin adjuvant, and demonstrate that two immunizations of mice with Betuvax-CoV-2 elicited high titers of RBD-specific antibodies. The candidate vaccine was also effective in stimulating a neutralizing antibody response and T cell immunity. The results indicate that Betuvax-CoV-2 has good potential for further development as an effective vaccine against SARS-CoV-2.
Top-30
Journals
|
1
2
3
|
|
|
Vaccines
3 publications, 27.27%
|
|
|
International Journal of Environmental Research and Public Health
1 publication, 9.09%
|
|
|
International Journal of Molecular Sciences
1 publication, 9.09%
|
|
|
Nanobiotechnology Reports
1 publication, 9.09%
|
|
|
Genes and Cells
1 publication, 9.09%
|
|
|
Journal of Antibiotics
1 publication, 9.09%
|
|
|
Scandinavian Journal of Immunology
1 publication, 9.09%
|
|
|
Vaccine
1 publication, 9.09%
|
|
|
1
2
3
|
Publishers
|
1
2
3
4
5
|
|
|
MDPI
5 publications, 45.45%
|
|
|
Cold Spring Harbor Laboratory
1 publication, 9.09%
|
|
|
Pleiades Publishing
1 publication, 9.09%
|
|
|
PJSC Human Stem Cells Institute
1 publication, 9.09%
|
|
|
Springer Nature
1 publication, 9.09%
|
|
|
Wiley
1 publication, 9.09%
|
|
|
Elsevier
1 publication, 9.09%
|
|
|
1
2
3
4
5
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.